UCSF researchers designed new drug candidates that potently block MPro, a viral enzyme that's crucial for SARS-CoV-2 replication. One of these drug candidates, AVI-4516, is shown (center) bound to the ...
A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of ...
The RNA-based Nipah virus, which causes acute respiratory illness and fatal encephalitis, can be transmitted from fruit bats to humans directly or indirectly via pigs or horses. Researchers at Wuhan ...
(A) A comprehensive analysis of caffeine binding to one of the spike proteins; (B, C) Caffeine interacts with critical amino acids in the SARS-CoV-2 S protein’s receptor-binding domain (RBD), ...
Over the last few years, the SARS-CoV-2 virus, responsible for COVID-19, has undergone significant changes, evolving from the original wild-type strains to the highly transmissible Omicron variant.
Viral mimic systems and other tech platforms could enable local testing of vaccine candidates and antiviral therapies. This ...
The COVID-19 pandemic highlighted the urgent need for effective therapeutic agents against SARS-CoV-2. Although vaccines helped control the spread of the virus, the emergence of new variants continues ...
The research by Turkish scientists who developed the 'invisible keys' technology in drug design offers a critical opportunity ...
FDA has approved Phase II trial for IN002.5.1 SARS-CoV-2 mRNA vaccine. This approval paves the way for the development of combined respiratory virus vaccines. We are thrilled with the FDA's approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results